CTMX Q1 2024 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$41M+76.4% YoY

Gross Profit

$41M100.0% margin

Operating Income

$12M28.1% margin

Net Income

$14M33.3% margin

EPS (Diluted)

$0.17

QoQ Revenue Growth

+55.8%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$185M

Total Liabilities

$216M

Stockholders' Equity

-$32M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41M	$23M	+76.4%
Gross Profit	$41M	$22M	+88.4%
Operating Income	$12M	-$6M	+306.2%
Net Income	$14M	-$3M	+516.5%